Copeland, A. and Younes, A. (2012). Current treatment strategies in Hodgkin lymphoma. Current Opinion in Oncology, 24, 466-474.
Copeland, A., et al. (2012). Phase I Study of Anti-CD19 Antibody-Drug Conjugate SAR3419 in Relapsed Lymphoma. Pan Pacific Lymphoma Conference (Abstract).
Copeland, A., et al. (2011). Results of a Phase I/II Study of the Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. Pan Pacific Lymphoma Conference (Abstract).
Copeland, A. Buglio, D. and Younes, A. (2010). Histone deacetylase inhibitors in lymphoma.Current Opinion in Oncology, 22, 431-436.
Copeland, A. and Younes, A. (2010). Brentuximab vedotin. Drugs of the future, 35, 797-.
Copeland, A.,et al. (2009). Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data. Blood (ASH Annual Meeting Abstracts);114: 1680.
Copeland, A., et al. (2009). Event-free survival (EFS) improved in patients with classical Hodgkin’s lymphoma given Rituximab+ABVD: Final. Pan Pacific Lymphoma Conference (Abstract).
Wedgwood, A., et al., (2007) Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. ASH Annual Meeting Abstracts. 110, 215-.
Wedgwood, A, et al., (2005). The lymphomas: Molecular pathways and novel therapeutic targets.Current Hematology Reports, 4, 324-334.
Wedgwood, A. and Younes, A. (2006). Targeting lymphoma cells and their microenvironment with novel antibodies. Clinical Lymphoma Myeloma, 7, S33-40.
Wedgwood, A. and Younes, A. (2009). Targeted therapy in lymphoma. In, Targeted therapy in cancer.
Wedgwood, A, et al. (2006). CD20+ nodal marginal zone B-cell lymphoma with CD20- recurrence as an intracranieal dural-based mass.Leukemia Lymphoma, 47, 2253-6.